Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. News
  7. Summary
    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ORPHAZYME A/S
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021 (Form 6-K)
PU
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021
AQ
10/05ORPHAZYME A/S : provides regulatory and financial updates (Form 6-K)
PU
10/05ORPHAZYME A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Ou..
MT
10/05ORPHAZYME A/S : provides regulatory and financial updates
AQ
09/06ORPHAZYME A/S : Final Deadline for Investors with Losses Exceeding $500K to Actively Parti..
BU
09/03THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the Class Acti..
BU
08/31ORPHAZYME A/S : Interim Report First Half 2021 Investor Call.pdf
PU
08/31ORPHAZYME A/S : Interim Report First Half 2021 (Form 6-K)
PU
08/31ORPHAZYME A/S : Interim Report First Half 2021
PU
08/31ORPHAZYME A/S : reports business highlights and financial results in Interim Report First ..
AQ
08/31Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/31Orphazyme A/S Maintains its Outlook for the Full Year 2021
CI
08/25Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021
GL
08/24ORPHAZYME A/S : CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of..
BU
More most relevant news
All news about ORPHAZYME A/S
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
DJ
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
DJ
10/18European ADRs Move Lower in Monday Trading
MT
10/14European ADRs Climb Higher in Thursday Trading
MT
10/08European ADRs Move Higher in Friday Trading
MT
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021 (Form 6-K)
PU
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021
AQ
10/05ORPHAZYME A/S : provides regulatory and financial updates (Form 6-K)
PU
10/05ORPHAZYME A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Ou..
MT
10/05ORPHAZYME A/S : provides regulatory and financial updates
AQ
More news
News in other languages on ORPHAZYME A/S
10/18Les ADR européens en baisse lundi
10/14Les ADR européens grimpent dans la journée de jeudi
10/08Les ADR européens sont en hausse vendredi
10/05Orphazyme déclare que l'examen européen de l'Arimoclomol est en cours ; relève ses prév..
09/23Les ADR européens sont en forte hausse ce jeudi
09/16Les ADR européens en baisse jeudi
09/15Hausse modérée des ADR européens mercredi, avec le rallye des valeurs énergétiques
08/31Orphazyme A/S maintient ses perspectives pour l'ensemble de l'année 2021
08/30Les ADR européens progressent légèrement dans les échanges de lundi
08/27Les ADR européens progressent de près de 1% vendredi matin
More news
Analyst Recommendations on ORPHAZYME A/S
06/21ORPHAZYME A/S : Guggenheim Downgrades Orphazyme to Sell From Neutral
MT
06/21ORPHAZYME A/S : Cowen Downgrades Orphazyme A/S to Market Perform From Outperform
MT
03/30ORPHAZYME A/S : BofA Securities Lowers Orphazyme A/S to Underperform From Neutral, Price T..
MT
More recommendations
Press releases
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021 (Form 6-K)
PU
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021
AQ
10/05ORPHAZYME A/S : provides regulatory and financial updates (Form 6-K)
PU
10/05ORPHAZYME A/S : provides regulatory and financial updates
AQ
09/06ORPHAZYME A/S : Final Deadline for Investors with Losses Exceeding $500K to Actively Parti..
BU
More press releases
Upcoming event on ORPHAZYME A/S